BackInterpharm Holdings Overview

Interpharm Holdings EBIT

Latest ebit for IPAH: $-20M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$3.94M
↑ 1.97% YoY

As of Dec 31, 2007

Annual EBIT (TTM)

-$19.72M
↓ 211.11% YoY

Trailing 12 months ending Dec 31, 2007

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Interpharm Holdings (IPAH) FAQ

The latest EBIT for IPAH is $-20M as of December 2007. That compares with $-6.3M in the prior-year period — down 211.1% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Interpharm Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, IPAH's EBIT moved from $-6.3M to $-20M — a 211.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Interpharm Holdings's operating scale or balance-sheet position.

Against its sector companies, IPAH currently prints $-20M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Interpharm Holdings's growth, margins, and balance sheet.

A EBIT figure of $-20M for IPAH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting IPAH's EBIT ($-20M), review year-over-year change from $-6.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.